Bridge Bio Upon Being Selected as an Innovative Company…”Expanding Research Personnel”
Bridge Bio Upon Being Selected as an Innovative Company…”Expanding Research Personnel”
  • Cho Eun, Reporter
  • 승인 2023.01.28 09:20
  • 수정 2023.01.28 09:20
  • 댓글 0
이 기사를 공유합니다

Tripling the Size of the Innovative New Drug Research Institute, Recruiting 10 or more research personnel
Strengthening clinical capabilities including clinical trial design and drug monitoring
[Photo courtesy of Bridge Biotherapeutics]
[Photo courtesy of Bridge Biotherapeutics]

Bridge Biotherapeutics (Bridge Bio), an 'innovative pharmaceutical company,' is to expand its new drug research center in Pangyo and strengthen its research forces.

 The company plans to focus on developing innovative new drug candidates by expanding research and clinical organizations.

On January 27th, an official from Bridge Bio said in a telephone interview with <WikiLeaks Korea>, “We are recruiting more than 10 researchers while expanding the Innovative New Drug Research Institute at our Pangyo headquarters by about three times this year. We will run a sustainable business by introducing our own development projects".

The official added, "We also hired a large number of people in the clinical team, such as clinical trial design, drug monitoring, clinical statistics, project management, and clinical operation.“

The company-affiliated research institute, the predecessor of the New Drug Research Institute, started research in 2016 in a laboratory space leased from Sungkyunkwan University. 

Then, it has moved to the Pangyo Research Institute in 2019 to start researching innovative new drugs, increasing the number of researchers from one to four, and this year, it will carry out large-scale recruitments along with space expansion.

The Boston Discovery Center, which is operated as a US subsidiary, is concentrating on research on discovering innovative anti-cancer drugs based on chemical proteomics technology, and is seeking collaboration through interacting with six world-class companies in Basel, Switzerland.

New drug pipelines, which are in the clinical development stage, include 'BBT-176', a candidate for non-small cell lung cancer targeting C797S-containing positive triple mutations (adopted from the Korea Research Institute of Chemical Technology), and 'BBT-207', a candidate for non-small cell lung cancer targeting C797S-containing positive double mutations (developed by Bridge Bio).
Bridge Bio has a strategy to achieve results in an "open innovation" method that incorporates its development capabilities into the capacity of introducing candidate materials strengthened through new drug development platform companies.

Recently, Bridge Bio was selected as an innovative pharmaceutical company certified by the Ministry of Health and Welfare in recognition of its innovativeness in research and development activities, achievements in open innovation activities, social responsibility, ethics, and transparency.

In the third quarter of last year, Bridge Bio's sales were 1 billion won with net loss of 33.8 billion won.

Its ordinary R&D expense was 26.9 billion won, up by 13 billion won from the same period last year. Through fund raising in the first half of last year, the company has 60 billion won and cash assets as of the third quarter settlement.

[WIKI KOREA=Cho Eun, Reporter]

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2023 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 :